Aman Chauhan1,2, Satya Das3, Rachel Miller4, Laura Luque5, Samuel N Cheuvront5, James Cloud6, Zach Tarter6, Fariha Siddiqui6, Robert A Ramirez7, Lowell Anthony8,4. 1. Division of Medical Oncology, University of Kentucky, Lexington, KY, USA. AmanChauhan@uky.edu. 2. Markey Cancer Center, University of Kentucky, 800 Rose Street CC402, Lexington, KY, 40536, USA. AmanChauhan@uky.edu. 3. Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Markey Cancer Center, University of Kentucky, 800 Rose Street CC402, Lexington, KY, 40536, USA. 5. Science & Technology, Entrinsic Bioscience Inc., Boston, MA, USA. 6. School of Medicine, University of Kentucky, Lexington, KY, USA. 7. Division of Oncology Ochsner Health System, New Orleans, LA, USA. 8. Division of Medical Oncology, University of Kentucky, Lexington, KY, USA.
Abstract
BACKGROUND: Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration solution (enterade® Advanced Oncology Formula) was found to have anti-diarrheal properties in preclinical models. METHODS: A retrospective chart review of all NET patients treated with enterade® AO was performed after IRB approval. RESULTS: Ninety-eight NET patients who had received enterade® AO at our clinic from May 2017 through June 2019 were included. Patients (N = 49 of 98) with follow up data on bowel movements (BMs) were included for final analysis. Eighty-four percent of patients (41/49) had fewer BMs after taking enterade® AO and 66% (27/41) reported more than 50% reduction in BM frequency. The mean number of daily BMs was 6.6 (range, 3-20) at baseline before initiation of therapy, while the mean number of BMs at 1 week time point post enterade® AO was 2.9 (range, 0-11). CONCLUSIONS: Our retrospective observations are encouraging and support prospective validation with appropriate controls in NET patients. This is first published report of the potential anti-diarrheal activity of enterade® AO in NET patients.
BACKGROUND:Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumorpatients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration solution (enterade® Advanced Oncology Formula) was found to have anti-diarrheal properties in preclinical models. METHODS: A retrospective chart review of all NET patients treated with enterade® AO was performed after IRB approval. RESULTS: Ninety-eight NET patients who had received enterade® AO at our clinic from May 2017 through June 2019 were included. Patients (N = 49 of 98) with follow up data on bowel movements (BMs) were included for final analysis. Eighty-four percent of patients (41/49) had fewer BMs after taking enterade® AO and 66% (27/41) reported more than 50% reduction in BM frequency. The mean number of daily BMs was 6.6 (range, 3-20) at baseline before initiation of therapy, while the mean number of BMs at 1 week time point post enterade® AO was 2.9 (range, 0-11). CONCLUSIONS: Our retrospective observations are encouraging and support prospective validation with appropriate controls in NET patients. This is first published report of the potential anti-diarrheal activity of enterade® AO in NET patients.
Authors: Diana D Shi; David P Yuppa; Trevor Dutton; Lauren K Brais; Sarah L Minden; Ilana M Braun; Matthew H Kulke; Jennifer A Chan; Fremonta L Meyer Journal: Cancer Date: 2017-03-07 Impact factor: 6.860
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Aura D Herrera-Martínez; Johannes Hofland; Leo J Hofland; Tessa Brabander; Ferry A L M Eskens; María A Gálvez Moreno; Raúl M Luque; Justo P Castaño; Wouter W de Herder; Richard A Feelders Journal: Drugs Date: 2019-01 Impact factor: 9.546
Authors: Boris G Naraev; Magnus Halland; Daniel M Halperin; Amy J Purvis; Thomas M OʼDorisio; Thorvardur R Halfdanarson Journal: Pancreas Date: 2019-09 Impact factor: 3.327
Authors: J A Maroun; L B Anthony; N Blais; R Burkes; S D Dowden; G Dranitsaris; B Samson; A Shah; M P Thirlwell; M D Vincent; R Wong Journal: Curr Oncol Date: 2007-02 Impact factor: 3.677